In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir

Ledipasvir (LDV; GS-5885), a component of Harvoni (a fixed-dose combination of LDV with sofosbuvir [SOF]), is approved to treat chronic hepatitis C virus (HCV) infection. Here, we report key preclinical antiviral properties of LDV, including in vitro potency, in vitro resistance profile, and activit...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Antimicrob Agents Chemother
Autors principals: Cheng, Guofeng, Tian, Yang, Doehle, Brian, Peng, Betty, Corsa, Amoreena, Lee, Yu-Jen, Gong, Ruoyu, Yu, Mei, Han, Bin, Xu, Simin, Dvory-Sobol, Hadas, Perron, Michel, Xu, Yili, Mo, Hongmei, Pagratis, Nikos, Link, John O., Delaney, William
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2016
Matèries:
Antiviral Agents
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4775926/
https://ncbi.nlm.nih.gov/pubmed/26824950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02524-15
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars